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Abstract  
Objective : To determine the effect of supplementation with increasing doses of 
docosahexaenoic acid (DHA), as the only n-3 polyunsaturated fatty acid (PUFA), on low-
density lipoprotein (LDL) redox status and oxidizability. 
Methods : Twelve healthy men aged 53 to 65 years ingested consecutive doses of DHA 
(200, 400, 800 and 1600 mg/day), each dose for two weeks.  
Results : The proportions of DHA increased dose-dependently in LDL phospholipids and 
cholesteryl esters, even after two weeks of supplementation with 200 mg/day DHA. The 
daily intake of 200, 400 and 800 mg DHA resulted in increased alpha-tocopherol 
concentrations, decreased MDA concentrations, and a longer lag time for copper-induced 
LDL oxidation. Supplementation with 1600 mg/day DHA had no effect on the above 
parameters. In plasma, concentrations of 4-hydroxy-hexenal, specifically derived from the 
peroxidation of n-3 fatty acids, significanty increased after 800 and 1600 mg DHA, 
representing 0.01% of plasma n-3 PUFAs, while 4-hydroxy-nonenal concentrations, 
derived from the peroxidation of n-6 fatty acids, did not change. 
Conclusion : Our results clearly show that an intake of 200 to 800 mg/day DHA may have 
protective and antioxidant effects on LDL and could represent optimal doses for 
cardiovascular disease prevention in a healthy population. 
 
Keywords : n-3 polyunsaturated fatty acids, antioxidant, peroxidation, low-density 
lipoproteins. 
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Introduction 
Prospective cohort studies suggest that consumption of fish or fish oils decreases the risk 
of cardiovascular diseases in Western populations [1]. This is thought to be due to their 
content in long-chain n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic 
acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3). Some recommendations 
for long-chain n-3 PUFAs intake for cardiovascular health and primary cardiovascular 
disease prevention have been issued by scientific organizations and government agencies 
(about 200-500 mg/day depending on countries [2,3]). However, there currently is no 
specific recommendation for DHA (or EPA) individually.  
Dietary supplementation with PUFAs leads to an increased proportion of these fatty acids 
in plasma lipoproteins, cell and tissue lipids. Taking into account the high susceptibility of 
the highly unsaturated fatty acids to undergo non-enzymatic peroxidation, enrichment of 
low-density lipoproteins (LDL) in DHA may increase their susceptibility to oxidation and 
result in enhanced risk for atherosclerosis [4]. Although many studies have determined the 
effects of dietary n-3 PUFAs or fish oils on the susceptibility of LDL to oxidation, results 
were discordant showing either a detrimental, beneficial effect or an absence of effect. 
In order to define the most adequate dose of DHA in a healthy population, we performed a 
dose-response study in healthy middle-aged men and examined the response of blood cells 
[5] and LDL to DHA dietary intake. Both tocopherol concentrations and lipid peroxide 
levels of LDL and their oxidizability in response to copper sulphate were investigated. 
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Methods 
 
Study design 
 
Twelve healthy men volunteers, aged 53 to 65 years, were recruited. Based on a pretrial 
power analysis, a minimum of six subjects provided 90% power to detect a 25% difference 
in platelet MDA and phosphatidylethanolamine DHA at P < 0.05. The subjects were 
normolipidemic, nonsmokers, did not use any medication or vitamin supplements and were 
asked to keep their dietary habits throughout the study. The volunteers received DHA-rich 
capsules (Pro-Mind, Decola, Belgium). Each capsule contained 200 mg DHA in 
triglycerides from algal oil, 0.125 mg DL-α-tocopherol and 0.125 mg ascorbyl palmitate. 
Fatty acid composition of the supplement, expressed as mol %, was 40% DHA, 1.2% 18:2 
n-6, 22.2% monounsaturated fatty acids (2% 16:1 n-7 and 20.2% 18:1 n-9) and 36.6% 
saturated fatty acids (6.6% 12:0, 16% 14:0 and 14% 16:0). The volunteers ingested 
consecutive doses of  200, 400, 800 and 1600 mg/day DHA, each period lasting for two 
weeks, followed by an 8-week wash out (WO) period. Compliance to the study (99%) was 
assessed by the number of capsules returned and the measurement of DHA levels in 
plasma [5] and LDL. The study was approved by the local ethical committee and written 
informed consent was obtained from all subjects.  
 
Blood collection 
Blood was collected in ACD (acid-citrate-dextrose)-containing Vacutainer tubes after 
overnight fasting before the start of the intervention (0), at the end of each 2-week period 
and after 8-week post-supplementation (WO). The blood was immediately centrifuged at 
200 g for 17 min at 20°C to get platelet-rich plasma and remaining blood was then 
centrifuged at 1500 g for 10 min to isolate plasma supernatant. 
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Low-density lipoprotein isolation 
LDL (density 1.019-1.063 g.ml-1) were separated from plasma containing 2.7 mM EDTA 
by potassium bromide stepwise density gradient ultracentrifugation [6] in a TLA 100.3 
fixed-angle rotor of a Beckman TL-100 ultracentrifuge. The LDL fraction was dialyzed 
extensively against phosphate buffered saline (PBS, pH 7.2) containing 1mM EDTA. Last 
dialysis was performed in PBS without EDTA. The concentration of protein was 
immediately estimated using the Bradford assay [7].  
 
Vitamin E determinations 
 
Tocopherol concentrations in LDL were determined by reversed-phase high-performance 
liquid chromatography (RP-HPLC). Briefly, following extraction with hexane in the 
presence of tocol and δ-tocopherol as internal standards, tocopherol isomers were detected 
and quantified by fluorimetry (excitation 295 nm, emission 340 nm) [8].  
 
Malondialdehyde measurements 
 
Overall lipid peroxidation was evaluated by quantitation of malondialdehyde (MDA) in 
LDL particles according to the method of Therasse & Lemonnier [9]. Briefly, TBA-MDA 
adducts were separated by RP-HPLC and measured by fluorimetry (excitation 515 nm, 
emission 553 nm).  
 
Fatty acid compositions of LDL phospholipids and cholesteryl esters 
Following extraction with ethanol:chloroform  (1:2, vol/vol), lipid classes were separated 
by thin-layer chromatography with hexane/diethyl ether/acetic acid (80:20:1, vol/vol/vol) 
into phospholipids, triglycerides and cholesteryl esters [10]. The phospholipid and 
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cholesteryl ester zones were scrapped off, treated with trifluoride boron/methanol for 90 
minutes at 100°C, and extracted twice with isooctane. Fatty acid methyl esters were 
separated by gas-liquid chromatography, using an HP 6890 gas chromatograph equipped 
with a SP 2380 capillary column (30 m x 0.25 mm ; Supelco, Bellefonte, PA, USA). 
 
Copper-induced LDL oxidation 
Aliquots of freshly dialyzed LDL (50 µg protein/mL) were oxidized in the presence of 1 
µM CuSO4 within the day following last dialysis. The oxidation of LDL was monitored by 
measuring the increased formation of conjugated dienes [11] at 234 nm every minute for 
60 minutes and every 5 minutes for 8 hours in a Kontron computer-linked 
spectrophotometer. The lag time was graphically defined for each oxidation curve as the 
time from the addition of CuSO4 until the intersection of the tangent with the baseline. 
 
Hydroxy-alkenal concentrations in plasma 
4-hydroxy-nonenal (4-HNE) and 4-hydroxy-hexenal (4-HHE) in their free forms were 
analyzed and quantified by gas chromatography-mass spectrometry (GC-MS) according to 
the procedure described by Van Kuijk et al. [12] modified as follows. Plasma samples, in 
the presence of deuterated d3-4-HNE and d3-4-HHE, were treated with O-2,3,4,5,6-
pentafluorobenzyl hydroxylamine hydrochloride for 30 minutes at room temperature. After 
acidification, pentafluorobenzyloxime derivatives were extracted with methanol/hexane 
and the hydroxyl groups were converted into trimethylsilylether with N,O-
Bis(trimethylsilyl)trifluoroacetamide. The pentafluorobenzyloxime, trimethylsilylether 
derivatives of 4-HNE (O-PFB-TMS-4-HNE) and 4-HHE (O-PFB-TMS-4-HHE) were 
analyzed by negative ion chemical ionization (NICI) GC-MS as previously described [13]. 
 7
 
Statistics 
Results are expressed as the mean ± S.E.M. for the 12 subjects, except for the WO period 
(n=11) and plasma hydroxy-alkenal concentrations (n=7). Comparisons between groups 
were performed using a non parametric Friedman test. Differences between values at two-
week supplementation periods or wash-out period and baseline values were determined by 
using a non parametric Wilcoxon post-test. A Spearman's correlation test was also used to 
determine correlations between parameters. Statistical significance was established at P < 
0.05. StatView for Windows (version 5.0.0.0 ; Albacus Corp., Baltimore, MD, USA) was 
used for statistical analysis. 
 8
 
Results 
Fatty acid composition of LDL phospholipids 
The proportions of the main fatty acids present in LDL phospholipids are listed in Table 1. 
Compared to baseline, there was a dose-dependent increase in the proportion of  DHA in 
LDL phospholipids after each supplementation period. This corresponds to an increase of 
18% after 200 mg DHA for two weeks, 49% after 400 mg DHA for two additional weeks, 
84% after 800 mg DHA and 114%  after 1600 mg DHA. DHA proportion returned to 
baseline after the WO period. Ingestion of  400, 800 and 1600 mg DHA also led to 
significant increases of EPA proportions in LDL phospholipids by 42, 43 and 65%, 
respectively. Proportion of EPA returned to baseline at the end of the 8-week WO period. 
In addition, there was a decrease by 35% in docosapentaenoic acid (22:5 n-3) proportion 
following supplementation with the highest dose of DHA. Concerning n-6  PUFAs, 
proportions of linoleic acid (18:2 n-6) significantly decreased after 800 and 1600 mg DHA 
and proportions of arachidonic acid (20:4 n-6) decreased after ingestion of DHA ranging 
from 200 to 1600 mg DHA. Linoleic and arachidonic acids proportions returned to 
baseline values after the WO period. 
 
Fatty acid composition of LDL cholesteryl esters 
As shown in Table 2, the ingestion of increasing doses of DHA resulted in a stepwise 
increase in its proportion in cholesteryl esters : 20%, 57%, 88% and 148%, after 200, 400, 
800 and 1600 mg DHA, respectively. Proportion of EPA increased significantly after each 
DHA supplement until two-fold after the highest dose. DHA and EPA proportions did not 
completely return to baseline levels after the WO period. No differences were observed for 
oleic (18:1 n-9) and linoleic acids between each step of supplementation and pre-
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supplementation period and the proportion of arachidonic acid decreased by 11 % after 
1600 mg DHA.  
 
Tocopherol concentrations in LDL 
As shown in Figure 1A, supplementation with 200, 400 and 800 mg DHA resulted in an 
increase by 27, 20 and 17% of α-tocopherol concentrations, respectively, when compared 
with baseline values. There was no significant change of α-tocopherol concentrations after 
1600 mg DHA and the WO period compared with baseline concentration. γ-tocopherol 
concentrations also increased after 200 mg/day DHA for 2 weeks compared with baseline 
concentrations (1.50 ± 0.22 versus 1.16 ± 0.14 nmol/mg protein respectively, P < 0.05, 
n=12) but did not change significantly after 400 mg (1.25 ± 0.14 nmol/mg protein), 800 mg 
(1.31 ± 0.16 nmol/mg protein), 1600 mg DHA (1.17 ± 0.11 nmol/mg protein) and the WO 
period (1.18 ± 0.13 nmol/mg protein).  
 
Malondialdehyde concentrations in LDL 
When compared to baseline values, MDA concentrations significantly decreased by 37%, 
45% and 25% after 200, 400 and 800 mg DHA supplements, respectively (Figure 1B). No 
change in MDA level was observed after the highest dose (1600 mg DHA). MDA 
concentration returned to baseline value after the WO period. 
 
Susceptibility of LDL to copper-induced oxidation  
The effect of DHA on LDL susceptibility to oxidation in vitro was derived from the 
formation of conjugated dienes upon addition of cupric ions to LDL and the corresponding 
lag time to oxidation (Figure 2). Supplementation with DHA resulted in significant 
increases in lag times after doses ranging from 200 to 800 mg DHA, compared to the pre-
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supplementation lag time. The maximum increase (34%) was observed after 400 mg DHA. 
There were no differences in the lag time after the highest dose of DHA and the WO 
period, compared with baseline. 
 
Concentrations of 4-hydroxy-nonenal and 4-hydroxy-hexenal in plasma 
4-HNE is one of the major aldehydes derived from the peroxidation of n-6 fatty acids, 
essentially linoleic and arachidonic acids, while 4-HHE is the major aldehyde derived from 
the peroxidation of n-3 fatty acids. As shown in Table 3, plasma 4-HNE concentrations did 
not vary significantly prior to and post supplementation periods with DHA. Compared to 
its baseline concentration in plasma, no significant changes of plasma 4-HHE levels were 
observed after supplementation with 200 and 400 mg DHA, although there was a trend. 
Supplementation with 800 mg DHA resulted in a 7.2-fold increase of plasma 4-HHE 
concentration, reaching 10.5-fold after the highest dose of supplementation (1600 mg 
DHA). Hydroxy-alkenal concentrations returned to baseline ones after the WO period. 
 
 11
 
Discussion  
The salient findings of the present study are that the supplementation of healthy men 
volunteers with 200, 400 and 800 mg/day DHA during two-week consecutive periods can 
improve LDL redox status and protect LDL against in vitro oxidation.  
Concerning LDL redox status, our results show a significant and noticeable increase of α-
tocopherol concentration in LDL following supplementation with 200 to 800 mg/day 
DHA. It is very unlikely that the increased α-tocopherol LDL concentration following 
DHA supplementation was due to the tiny amount of α-tocopherol contained in each 
capsule (around 0.5% of the normal daily intake). In addition, supplementation with 1600 
mg/day DHA had no effect on tocopherol concentrations. No other study has ever reported 
that DHA or n-3 PUFAs may lead to increased concentrations of vitamin E in LDL. In 
plasma, most studies either reported no effect [14] or decreases of plasma vitamin E 
[15,16] following the supplementation with n-3 PUFAs. Only one study reported increases 
of plasma α-tocopherol and β-carotene concentrations [17]. We also show for the first time 
that supplementation with 200 to 800 mg DHA resulted in lower concentrations of  MDA 
in LDL. The concentration of MDA, one of the end-products of lipid peroxidation, was 
assessed in LDL by the separation and quantification of the TBA-MDA adducts by HPLC. 
Some previous studies showed an increase of thiobarbituric acid reactive substances 
(TBARS) levels in plasma after high doses of n-3 PUFAs (from 4 to 15g/day fish oils) 
[16,18,19] whereas others reported no effect on TBARS formation in plasma and LDL 
after lower doses of n-3 PUFAs (from 0.3 to 2.4g fish oil/day) [17,20].  
Despite numerous studies, there is no consensus on the effects of n-3 PUFAs on LDL 
oxidation and very few have been performed with DHA alone and none with increasing 
doses of DHA. Most intervention studies reported an increased in vitro oxidation of LDL 
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following supplementation with fish oils [21-23]. However, some studies showed that fish 
oil [24], n-3 PUFAs [25] or DHA [26] did not increase the susceptibility of LDL to 
oxidation and even decreased it [27]. Such discrepancies may be related to differences in 
the populations studied, in the composition and dosage of the n-3 PUFAs supplement, in 
the duration of studies and in methodologies. We show that supplementation with 200 to 
800 mg/day DHA increased the lag time for copper-induced LDL oxidation, indicating a 
decreased susceptibility of LDL to oxidation. Since the lag phase is inversely corelated 
with severity of clinical atherosclerosis [28], the prolongation of the lag phase with DHA 
may prove beneficial. The length of the lag period is known to be determined by the 
concentrations of antioxidants, the concentrations of substrates available for oxidation and 
the amount of endogenous peroxides [11]. In our study, the candidate molecules 
responsible for an increased lag time could be the lesser amount of lipid peroxides attained 
after DHA supplementation because the lag time was inversely correlated with MDA 
concentration (P < 0.05, data not shown). Supplementation with 1600 mg DHA had no 
effect on the lag phase compared to baseline, and corroborates the absence of effect of this 
dose on LDL redox status. These results strengthen in vitro results [29] showing 
differential effects of DHA on platelet redox status with antioxidant and prooxidant effects 
at low and high DHA concentrations and no effect at moderate DHA concentrations. 
Our results confirm that supplementation with DHA dose-dependently increased DHA 
proportion in LDL lipids [20]. Noteworthy, daily supplementation with as little as 200 mg 
DHA for 2 weeks led to significant increases of DHA in phospholipids and cholesteryl 
esters. EPA proportion significantly increased in both LDL phospholipids and cholesteryl 
esters after supplementation with 400 to 1600 mg DHA, indicating that some 
retroconversion of DHA to EPA may have occurred. Based on LDL phospholipid data, the 
retroconversion of DHA to EPA was estimated to 12% at the end of the 8-week 
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supplementation period. This estimated value is close to the one estimated in serum 
phospholipids after 6-week supplementation with an EPA-free preparation of DHA 
(11.3%) [30]. Supplementation with 1600 mg DHA also resulted in a decreased proportion 
of docosapentaenoic acid (22:5 n-3) in LDL phospholipids, corroborating  other additional 
results of the present study in plasma and platelets [5]. Such a decrease could reflect the 
competition of 22:5 n-3 with DHA for esterification at the sn-2 position into phospholipids. 
In addition, plasma concentrations of triglycerides, total cholesterol, LDL-cholesterol 
remained unchanged throughout the study [5]. The only significant change was a slight 
increase of HDL-cholesterol after 1600mg DHA compared with baseline (1.60 ± 0.12 
versus 1.43 ± 0.09 nmol/L, n=12, P < 0.05). Besides LDL parameters, 4-HNE and 4-HHE 
were measured in some of plasma samples which allowed us to differentiate between 
specific oxidation of n-6 PUFAs and that of n-3 PUFAs, respectively. While free 4-HNE 
concentrations did not vary at all throughout the supplementation periods, the intake of 800 
and 1600 mg DHA supplements resulted in significant increased concentrations of  4-HHE 
but represented as low as 0.01% of plasma n-3 PUFAs amount. Our results indicate that 
DHA was specifically peroxidized into 4-HHE [31] but to a very small extent. Although 
further studies are required, we may speculate that the formation of 4-HHE from DHA 
might be a way to explain the antioxidant effect of DHA which might serve as a primary 
target for oxidative stress, sparing endogenous antioxidants at an early stage. 
The present study has some limitations such as the sample size and  therefore our results 
need to be confirmed on a larger scale. 
In conclusion, our results show that supplementation of healthy men with 200-800 mg 
DHA/day may have protective and antioxidant effects on LDL and are supportive of the 
global recommendations for long-chain n-3 PUFAs for primary prevention of coronary 
diseases [32]. It gives new information on the most adequate doses of DHA individually to 
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confer benefits for the prevention against LDL oxidation and possibly for cardiovascular 
health. 
 
Acknowledgements 
We are grateful to the volunteers for their reliable participation and to the staff from 
CRNH for their expert blood drawing and some lipid analyses. This work was supported 
by INSERM, Groupe Lipides et Nutrition (GLN) and Agence Nationale de la Recherche 
(ANR) 2005 "Cardiovasculaire, Obésité et Diabète". Catherine Calzada is supported by 
CNRS. 
 15
 
Abbreviations 
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; 4-HNE, 4-hydroxy-nonenal; 4-
HHE, 4-hydroxy-hexenal; LDL, low-density lipoproteins; MDA, malondialdehyde; 
PUFAs, polyunsaturated fatty acids; WO, wash out. 
 16
 
References 
 
[1] Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between 
fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 
1985;312:1205-9. 
[2] SACN. Advice on fish consumption: Benefits and risks. in: 
http://www.foodstandards.gov.uk/, (Ed.), UK Scientific Advisory Committee on Nutrition, 
2004. 
[3] ISSFAL. Recommendations for intake of polyunsaturated fatty acids in healthy adults. 
International Society for the Study of Fatty Acids and Lipids. in: 
http://www.issfal.org.uk/lipid-matters/issfal-policystatements/issfal-policy-statement-3-
10.html., (Ed.), International Society for the Study of Fatty Acids and Lipids, 2004. 
[4] Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants 
in atherogenesis. An appraisal. J Lipid Res 1999;40:2143-57. 
[5] Guillot N, Caillet E, Laville M, Calzada C, Lagarde M, Véricel E. Increasing intakes of 
long-chain omega 3 docosahexaenoic acid: effects on platelet functions and redox status in 
healthy men. FASEB J (in press). 
[6] Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of 
ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53. 
[7] Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
1976;72:248-54. 
[8] Calzada C, Coulon L, Halimi D, Le Coquil E, Pruneta-Deloche V, Moulin P, Ponsin G, 
Véricel E, Lagarde M. In vitro glycoxidized low-density lipoproteins and low-density 
 17
lipoproteins isolated from type 2 diabetic patients activate platelets via p38 mitogen-
activated protein kinase. J Clin Endocrinol Metab 2007;92:1961-4. 
[9] Therasse J, Lemonnier F. Determination of plasma lipoperoxides by high-performance 
liquid chromatography. J Chromatogr 1987;413:237-41. 
[10] Lagarde M, Drouot B, Guichardant M, Dechavanne M. In vitro incorporation and 
metabolism of some icosaenoic acids in platelets. Effect on arachidonic acid oxygenation. 
Biochim Biophys Acta 1985;833:52-8. 
[11] Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and 
antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992;13:341-90. 
[12] van Kuijk FJ, Siakotos AN, Fong LG, Stephens RJ, Thomas DW. Quantitative 
measurement of 4-hydroxyalkenals in oxidized low-density lipoprotein by gas 
chromatography-mass spectrometry. Anal Biochem 1995;224:420-4. 
[13] Bacot S, Bernoud-Hubac N, Baddas N, Chantegrel B, Deshayes C, Doutheau A, 
Lagarde M, Guichardant M. Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 
4-HNE to ethanolamine phospholipid subclasses. J Lipid Res 2003;44:917-26. 
[14] Luostarinen R, Wallin R, Wibell L, Saldeen T. Vitamin E supplementation 
counteracts the fish oil-induced increase of blood glucose in humans. Nutr Res 
1995;15:953-68. 
[15] Brude IR, Drevon CA, Hjermann I, Seljeflot I, Lund-Katz S, Saarem K, Sandstad B, 
Solvoll K, Halvorsen B, Arnesen H, Nenseter MS. Peroxidation of LDL from combined-
hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants. 
Arterioscler Thromb Vasc Biol 1997;17:2576-88. 
[16] Nair PP, Judd JT, Berlin E, Taylor PR, Shami S, Sainz E, Bhagavan HN. Dietary fish 
oil-induced changes in the distribution of alpha-tocopherol, retinol, and beta-carotene in 
 18
plasma, red blood cells, and platelets: modulation by vitamin E. Am J Clin Nutr 
1993;58:98-102. 
[17] Turley E, Wallace JM, Gilmore WS, Strain JJ. Fish oil supplementation with and 
without added vitamin E differentially modulates plasma antioxidant concentrations in 
healthy women. Lipids 1998;33:1163-7. 
[18] Harats D, Dabach Y, Hollander G, Ben-Naim M, Schwartz R, Berry EM, Stein O, 
Stein Y. Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma 
lipoproteins. Atherosclerosis 1991;90:127-39. 
[19] Suzukawa M, Abbey M, Howe PR, Nestel PJ. Effects of fish oil fatty acids on low 
density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 
1995;36:473-84. 
[20] Higgins S, Carroll YL, McCarthy SN, Corridan BM, Roche HM, Wallace JM, O'Brien 
NM, Morrissey PA. Susceptibility of LDL to oxidative modification in healthy volunteers 
supplemented with low doses of n-3 polyunsaturated fatty acids. Br J Nutr 2001;85:23-31. 
[21] Sorensen NS, Marckmann P, Hoy CE, van Duyvenvoorde W, Princen HM. Effect of 
fish-oil-enriched margarine on plasma lipids, low-density-lipoprotein particle composition, 
size, and susceptibility to oxidation. Am J Clin Nutr 1998;68:235-41. 
[22] Egert S, Somoza V, Kannenberg F, Fobker M, Krome K, Erbersdobler HF, Wahrburg 
U. Influence of three rapeseed oil-rich diets, fortified with alpha-linolenic acid, 
eicosapentaenoic acid or docosahexaenoic acid on the composition and oxidizability of 
low-density lipoproteins: results of a controlled study in healthy volunteers. Eur J Clin 
Nutr 2007;61:314-25. 
[23] Turini ME, Crozier GL, Donnet-Hughes A, Richelle MA. Short-term fish oil 
supplementation improved innate immunity, but increased ex vivo oxidation of LDL in 
man--a pilot study. Eur J Nutr 2001;40:56-65. 
 19
[24] Higdon JV, Du SH, Lee YS, Wu T, Wander RC, Supplementation of postmenopausal 
women with fish oil does not increase overall oxidation of LDL ex vivo compared to 
dietary oils rich in oleate and linoleate. J Lipid Res 2001;42:407-18. 
[25] Bonanome A, Biasia F, De Luca M, Munaretto G, Biffanti S, Pradella M, Pagnan A. 
n-3 fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic 
hemodialyzed subjects. Am J Clin Nutr 1996;63:261-6. 
[26] Mesa MD, Buckley R, Minihane AM, Yaqoob P. Effects of oils rich in 
eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of 
low-density lipoprotein. Atherosclerosis 2004;175:333-43. 
[27] de Ruiz GJ, Mertxe de R, del Cerro A, de Fernandez LE, Amiano P, Dorronsoro M. 
Habitual fish intake is associated with decreased LDL susceptibility to ex vivo oxidation. 
Lipids 2002;37:333-41. 
[28] Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low- 
density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-
6. 
[29] Véricel E, Polette A, Bacot S, Calzada C, Lagarde M. Pro- and antioxidant activities 
of docosahexaenoic acid on human blood platelets. J Thromb Haemost 2003;1:566-72. 
[30] Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic 
acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in 
vegetarian subjects. J Nutr 1996;126:3032-9. 
[31] Van Kuijk FJ, Holte LL, Dratz EA. 4-Hydroxyhexenal: a lipid peroxidation product 
derived from oxidized docosahexaenoic acid. Biochim Biophys Acta 1990;1043:116-8. 
[32] Kris-Etherton PM, Grieger JA, Etherton TD. Dietary reference intakes for DHA and 
EPA. Prostaglandins Leukot Essent Fatty Acids (in press). 
 
 20
 
 
 Figure legends 
 
Figure 1. α-Tocopherol (A) and malondialdehyde (B) concentrations in LDL. 
Results are means ± S.E.M. for the 12 volunteers (except for the WO, n=11) at baseline 
(0), after each 2-week period of supplementation (200, 400, 800 and 1600 mg/day DHA) 
and at the end of the WO period. P < 0.05 compared with baseline. 
 
Figure 2. Lag time for conjugated diene formation in copper-oxidized LDL. 
LDL (50 µg protein /mL) were oxidized in the presence of  1 µM CuSO4 and the lag time 
was calculated from the time courses of conjugated diene formation. Results are means ± 
S.E.M. for the 12 volunteers (except for the WO, n=11). P < 0.05 compared with baseline. 
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 Table 1. Fatty acid composition of LDL phospholipids. 
DHA (mg/day) 
Fatty acid (mol %) 0 200 400 800 1600 0 (WO) 
Palmitic  
(16:0) 
32.4 ± 0.4 
 
  32.4 ± 0.5 
 
32.3 ± 0.7 
 
 33.4 ± 0.7 
 
33.5 ± 0.5 
 
  33.6 ± 0.7
 
Stearic  
(18:0) 
15.5 ± 0.6 
 
  14.9 ± 0.3 
  
15.1 ± 0.3 
 
 14.9 ± 0.3 
  
15.0 ± 0.4 
 
14.8 ± 0.5 
 
Oleic  
(18:1 n-9) 
10.0 ± 0.5 
 
10.0 ± 0.5 
 
  9.3 ± 0.5 
 
   9.8 ± 0.5 
 
  9.6 ± 0.6 
 
10.4 ± 0.6 
 
Linoleic  
(18:2 n-6) 
21.8 ± 0.7 
 
21.7 ± 0.6 
 
21.4 ± 0.8 
 
  20.2 ± 0.7*
 
  19.8 ± 0.9* 
 
20.5 ± 0.7 
 
Dihomo-γ-linolenic  
(20:3 n-6) 
  2.8 ± 0.3 
 
  2.5 ± 0.1 
 
  2.5 ± 0.1 
 
   2.4 ± 0.1 
 
  1.9 ± 0.1 
 
   2.5 ± 0.1 
 
Arachidonic  
(20:4 n-6) 
  7.8 ± 0.4 
 
    7.3 ± 0.4*
 
    7.3 ± 0.5*
 
    6.7 ± 0.4*
 
    6.1 ± 0.3* 
 
   7.2 ± 0.4 
  
Eicosapentaenoic  
(20:5 n-3) 
  0.7 ± 0.1 
 
 0.8 ± 0.1 
 
    1.0 ± 0.2*
 
    1.0 ± 0.1*
 
    1.2 ± 0.2* 
 
   1.0 ± 0.2 
 
Docosanoic  
(22:0) 
  1.3 ± 0.3 
 
 1.6 ± 0.1 
 
  1.7 ± 0.2 
 
  1.6 ± 0.2 
 
  1.6 ± 0.1 
 
   1.6 ± 0.2 
 
Docosapentaenoic  
(22:5 n-3) 
  0.7 ± 0.1 
 
   0.7 ± 0.04 
 
  0.7 ± 0.1 
 
  0.6 ± 0.1 
 
    0.5 ± 0.02* 
 
   0.8 ± 0.1 
 
Docosahexaenoic  
(22:6 n-3) 
  3.0 ± 0.2 
 
   3.5 ± 0.2* 
 
    4.4 ± 0.3*
 
    5.4 ± 0.3*
 
    6.3 ± 0.3* 
 
   3.2 ± 0.3 
 
Nervonic  
(24:1 n-9) 
  2.2 ± 0.3 
 
2.4 ± 0.2 
 
  2.1 ± 0.3 
 
  2.0 ± 0.2 
 
  2.2 ± 0.1 
 
   2.2 ± 0.2 
 
 
Results, expressed as mol % of main fatty acids, are means ± S.E.M. for the 12 volunteers  
(except for the WO, n=11) before (0), after each 2-week period of supplementation (200, 
400, 800 and 1600 mg/day DHA) and at the end of the WO period. 
* : P < 0.05 compared with baseline (0). 
 22
 
Table 2. Fatty acid composition of LDL cholesteryl esters. 
DHA (mg/day) 
Fatty acid (mol %) 0 200 400 800 1600 0 (WO) 
Palmitic  
(16:0) 
12.6 ± 0.3 12.4 ± 0.3 12.3 ± 0.5 12.9 ± 0.3 12.5 ± 0.2 12.8 ± 0.6 
Palmitoleic  
(16:1 n-7) 
  3.6 ± 0.4   3.4 ± 0.5   2.7 ± 0.2    3.6 ± 0.5   3.3 ± 0.6   4.1 ± 0.7 
Stearic  
(18:0) 
  1.1 ± 0.1   1.0 ± 0.1   1.0 ± 0.1   1.0 ± 0.1    0.8 ± 0.03   1.0 ± 0.1 
Oleic  
(18:1 n-9) 
20.5 ± 0.6 20.6 ± 0.7 19.8 ± 0.5 20.4 ± 0.6 20.4 ± 0.9 21.3 ± 1.0 
Linoleic  
(18:2 n-6) 
50.8 ± 1.3 51.4 ± 1. 5 52. 8 ± 1.4 50.7 ± 1.3 51.5 ± 1.7 49.2 ± 2.1 
Gamma-linolenic  
(18:3 n-6) 
  0.9 ± 0.1   0.9 ± 0.1   0.7 ± 0.1   0.7 ± 0.1    0.6 ± 0.1   0.9 ± 0.2 
Arachidonic  
(20:4 n-6) 
  6.0 ± 0.4   5.9 ± 0.3   5.9 ± 0.5    5.6 ± 0.4     5.3 ± 0.3*   5.9 ± 0.3 
Eicosapentaenoic  
(20:5 n-3) 
  0.7 ± 0.1    0.8 ± 0.1*     1.1 ± 0.2*    1.1 ± 0.1*     1.4 ± 0.2*     1.1 ± 0.1*
Docosahexaenoic  
(22:6 n-3) 
  0.5 ± 0.1   0.6 ± 0.1*     0.8 ± 0.1*    1.0 ± 0.1*     1.3 ± 0.1*     0.6 ± 0.1*
 
Results, expressed as mol % of main fatty acids, are means ± S.E.M. for the 12 volunteers  
(except for the WO, n=11) before (0), after each 2-week period of supplementation (200, 
400, 800 and 1600 mg/day DHA) and at the end of the WO period. 
* : P < 0.05 compared with baseline (0).  
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Table 3. Plasma 4-hydroxy-nonenal (4-HNE) and 4-hydroxy-hexenal (4-HHE) 
concentrations. 
 
DHA  4−ΗΝΕ 4−ΗΗΕ 
(mg/day) (ng/ml) (ng/ml) 
   
   
0 1.11 ± 0.34   1.01 ± 0.44 
200   1.00 ± 0.31   1.73 ± 0.60  
400  1.04 ± 0.32  3.25 ± 1.69 
800   1.24 ± 0.48     7.25 ± 2.41 * 
1600 0.91 ± 0.36  10.57 ± 3.68 * 
0 (WO) 0.73 ± 0.27 0.56 ± 0.12 
 
Results, expressed in ng/ml plasma, are means ± S.E.M. for 7 volunteers (except for the 
WO, n=6) before (0), after each 2-week period of supplementation (200, 400, 800 and 
1600 mg/day DHA) and at the end of the WO period. 
* : P < 0.05 versus baseline (0). 
 
